[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hoag Memorial Hospital Presbyterian\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":121},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,73,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643370","phase-2-a-phase-2-trial-of-61cu-nu101-petct-compared-against-current-standard-of-care-18f-piflufolastat-pylarify-petct-100643370",false,"NCT07635524","A Phase 2 Trial of 61Cu-NU101 PET\u002FCT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET\u002FCT.","A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T (61Cu-NU101) for Patients With Prostate Cancer","Inclusion Criteria:\n\n1. Biopsy proven prostate adenocarcinoma\n2. Age ≥ 18 years\n3. ECOG 0 or 2 4 .Oligometastatic disease (1-5 radiotracer avid disease sites) on 18F- piflufolastat PET\u002FCT within 30 days of trial recruitment\n\nExclusion Criteria:\n\n1. Known allergy\u002Fhypersensitivity to PSMA-targeted imaging agents\n2. Other active malignancy, other than the known prostate cancer","MALE","18 Years",{"count":19,"type":20},34,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this research is to test whether a new investigational Molecular Imaging (MI) agent called 61Cu-NU101 is equal to or better than a currently used MI agent, Pylarify, for the detection of prostate cancer metastases.\n\n34 participants with biopsy-proven prostate cancer and cancer seen on a Pylarify PET scan will be enrolled in this study.\n\nThe investigational 61Cu-NU101 PET\u002FCT will be perfromed. If there is a difference between the standard Pylarify exam and the investigational 61Cu-NU101 exam, a biopsy of one lesion that is different between the two exams may be performed.",[26],"Prostate Cancer",[28,29,30,31,32],"prostate","cancer","metastatic","radiotracer","metastases","NOT_YET_RECRUITING","2026-06-03",{"date":36,"type":37},"2026-06-09","ACTUAL",{"date":39,"type":20},"2026-08-01",{"date":41,"type":20},"2028-10-01",{"name":43,"class":44},"Hoag Memorial Hospital Presbyterian","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100572652","phase-1-a-phase-i-trial-of-61cu-nodaga-psma-for-patients-with-prostate-cancer-100572652","NCT06736054","A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer","Inclusion Criteria:\n\n1. Biopsy proven prostate adenocarcinoma\n2. Age ≥ 18 years\n3. ECOG 0 or 1\n4. At least one site of PSMA-positive disease on a PSMA-targeted PET\u002FCT performed within 30 days of trial recruitment\n5. Creatinine of ≤1.4 or Creatinine Clearance or ≥ 60 mL\u002Fminute.\n\nExclusion Criteria:\n\n1. Known allergy\u002Fhypersensitivity to PSMA-targeted imaging agents\n2. Other active malignancy, other than the known prostate cancer",{"count":53,"type":20},8,[55],"PHASE1","Molecular Imaging (MI) uses tracers which emit radiation to provide clinically valuable imaging for patient with cancer. Most current MI agents utilize Fluorine 18 or Gallium 68 as the positron emitter for PET imaging. However, these isotopes have short half-lives which limit the geographic distribution range of tracers made with these isotopes. Copper 61 (61Cu) has a 3.3 hour half-life, which would allow for far greater distribution range following radiotracer production.\n\nThis phase I trial will test the safety and effectiveness of a novel MI radiotracer that uses 61Cu as its positron emitting isotope and targets Prostate Specific Membrane Antigen (PSMA) for imaging prostate cancer. A successful trial will provide the ability to advance this novel 61Cu-NODAGA-PSMA radioisotope into phase II trials, as well as open a new paradigm into the production of MI radioisotopes with 61Cu.",[58],"Prostate Adenocarcinoma",[60,61,62],"PSMA","PET\u002FCT","Phase 1","RECRUITING","2024-12-12",{"date":66,"type":37},"2024-12-16",{"date":68,"type":37},"2024-10-14",{"date":70,"type":20},"2025-03-31",{"name":43,"class":44},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":80,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":72},"100366280","perioperative-mindfulness-proposal-100366280","NCT04049214","Perioperative Mindfulness Proposal","Feasibility Study to Determine the Effect of Meditation on Perioperative Pain and Distress in Newly Diagnosed Breast Cancer Patients","Inclusion Criteria:\n\n* Females 18 years of age or older\n* Subject must be able to speak and read English\n* Newly diagnosed with primary breast cancer\n* Will receive primary surgical treatment for their breast cancer diagnosis.\n* Undergoing lumpectomy with or without autologous reconstruction with or without contralateral surgery for symmetry with or without IORT or simple mastectomy without reconstruction\n* Breast cancer or DCIS\n\nExclusion Criteria:\n\n* Recurrent breast cancer\n* Current or history of major psychiatric diagnosis.\n* Subjects who are receiving neo-adjuvant chemotherapy\n* Subjects undergoing modified radical mastectomy or reconstruction\n* Subjects regular meditation practice within the past 12 months (defined as greater than twice weekly practice)\n* Subjects unwilling or unable to complete study materials or comply with study visits\n* Subjects with no access to email or a mobile phone (required to access meditations)\n* Subjects undergoing surgery outside Hoag\n* Subjects who have narcotic dependence as defined by regular weekly narcotic use before cancer diagnosis.\n* Re-excision after lumpectomy (subjects who require re-excision after initial enrollment will be excluded from final analysis and dropped from the study).","FEMALE",{"count":82,"type":20},24,[84],"NA","The purpose of this study is to determine if a regular meditation and breath work practice started before surgery and continued through post-surgical recovery can improve anxiety and pain related to breast cancer and its treatment.",[87,88],"Breast Cancer","DCIS","2024-10-09",{"date":91,"type":37},"2024-10-15",{"date":93,"type":37},"2019-07-31",{"date":95,"type":20},"2025-07-31",{"name":43,"class":44},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":72},"100416259","phase-2-pyl-in-patients-with-high-risk-and-biochemically-recurrent-prostate-cancer-100416259","NCT04700332","PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer","2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (PyL) in Patients With High Risk and Biochemically Recurrent Prostate Cancer","Inclusion Criteria:\n\n1. Male ≥ 18 years of age.\n2. Histologically confirmed adenocarcinoma of the prostate\n3. Patients meet one of the follow criteria:\n\nCohort 1: High risk prostate cancer (PSA \\>10, Gleason 8-10, or clinical stage \\>T2c) and planned prostatectomy or radiation therapy or Cohort 2: Biochemical prostate cancer relapse (Prostate Specific Antigen (PSA) \\> 0.2 ng\u002Fml in patients following prostatectomy or ≥ 2 ng\u002Fml more than the PSA nadir in patient following radiotherapy, as defined by the ASTRO-Phoenix criteria \\[18\\] and no evidence of malignancy on standard of care imaging for metastases (CT of the chest\u002Fabdomen\u002Fpelvis and bone scan) within 3 months.\n\nExclusion Criteria:\n\n1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n2. Patients who cannot undergo PET\u002FCT scanning because of weight limits. PET\u002FCT scanners may not be able to function with patients over 450 pounds.\n3. Change in therapy since standard of care imaging",{"count":105,"type":20},184,[23],"The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest\u002Fabdomen\u002Fpelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET\u002FCT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.",[26],[26,110,111,112],"DCFPyL PET\u002FCT","Staging","Biochemical relapse","2021-07-26",{"date":115,"type":37},"2021-07-27",{"date":117,"type":37},"2021-02-01",{"date":119,"type":20},"2022-12-15",{"name":43,"class":44},""]